Last updated: May 26, 2026
Executive summary: Suppliers for irbesartan plus hydrochlorothiazide span (1) generic API makers for irbesartan and HCTZ, (2) contract manufacturers for tablets (blend, compression, film coating, packaging), and (3) specialty ingredient and intermediate providers tied to irbesartan’s core chemistry. The supplier landscape is shaped by FDA ANDA demand, Abbreviated New Drug Application (ANDA) process chemistry, and patent/IP constraints that typically affect alternative manufacturing routes more than finished-dose tablet capabilities.
Which companies supply irbesartan and hydrochlorothiazide APIs for generic tablets?
Typical supplier archetypes
- API manufacturers (irbesartan, hydrochlorothiazide)
Provide bulk drug substance used for ANDA manufacturing.
- Intermediate and key starting material suppliers (irbesartan)
Provide the reaction intermediates used in irbesartan synthesis, often via GMP supply chains.
- Finished-dose contract manufacturers (FDF tablets)
Manufacture film-coated tablets, including formulation development, scale-up, and packaging.
Irbesartan API supply (high-level sourcing pattern)
- Irbesartan is commonly sourced from established Indian, Chinese, and global API plants with ANDA-ready GMP systems and validated impurity profiles.
- Supplier qualification for irbesartan generally depends on impurity control for both the API and any downstream solid-state impurities that can affect tablet stability.
Hydrochlorothiazide (HCTZ) API supply
- HCTZ is widely available from multiple GMP suppliers because it is a mature, high-volume API.
- Supply differentiators are typically batch consistency, residual solvent and heavy metal controls, and documented polymorph/particle attributes used for consistent tablet performance.
What GMP documentation matters when sourcing irbesartan API?
- Batch records, CoA with impurity spectrum, residual solvents, elemental impurities, and stability data.
- For ANDA manufacturers, suppliers often provide DMF-linked quality packages or ASMF filings supporting specific impurity limits and manufacturing controls.
What suppliers make irbesartan and hydrochlorothiazide finished-dose tablets (FDF)?
Finished-dose manufacturers for irbesartan/HCTZ tablets are usually contract or vertically integrated generic tablet suppliers.
Which manufacturing steps define the FDF supplier qualification for irbesartan/HCTZ tablets?
- Formulation: excipient selection for tablet hardness, dissolution, and stability.
- Blending: uniform distribution of API(s) to control content uniformity.
- Compression and coating: film coating parameters to protect stability and improve appearance.
- Packaging: moisture and light control packaging selection, which is critical for long shelf life in thiazide-containing products.
How many dosage strengths exist for irbesartan/HCTZ tablets that drive supplier line requirements?
Common market strengths include:
- 150 mg / 12.5 mg
- 300 mg / 12.5 mg
- 300 mg / 25 mg
Supplier capability must match the target strength mapping, coating specs, and blister/bottle packaging.
What excipient and packaging suppliers support irbesartan/HCTZ tablet production?
Which excipient categories are typically sourced by FDF manufacturers?
- Binders (for tablet strength)
- Disintegrants (for dissolution)
- Lubricants (for flow and ejection)
- Film coating polymers and colorants (for appearance and stability)
Packaging suppliers
- High-barrier blister film suppliers and HDPE bottle suppliers with appropriate desiccant systems are usually in scope because thiazide stability can be sensitive to moisture.
What intermediate suppliers support irbesartan API production?
Irbesartan’s synthesis uses specialized intermediates and protecting-group chemistry that requires tight impurity control.
Which intermediate types matter for supplier selection?
- Core heterocycle-building intermediates
- Functional group transformation intermediates (used to install substituents with defined stereochemistry)
- Final purification intermediates (used to reach ANDA impurity specs)
How does intermediate sourcing affect patent/IP and manufacturing risk?
- Alternative intermediate routes can trigger patent coverage depending on jurisdiction and claim scope (process patents are common around key steps in ARBs).
- Even when formulation IP is not central, manufacturing-process claims can constrain where and how API is made.
How do supplier choices impact ANDA regulatory readiness for irbesartan/HCTZ?
Orange Book and ANDA linkage: why suppliers coordinate by DMF/ASMF
- ANDA applicants typically align API supplier documentation with DMF/ASMF references to reduce regulatory friction.
- For combination products, applicant qualification also depends on bioequivalence evidence for the chosen formulation and manufacturing process.
What data packages are commonly requested from API suppliers
- Impurity qualification and control strategy
- Analytical methods validation and method transfer support
- Particle size distribution and polymorph controls
- Stability program adherence (long-term and accelerated)
What are the generic launch risks tied to supplier manufacturing routes?
Paragraph IV and process constraints
- If a supplier route falls within or closely follows patented process claims, the ANDA applicant may face litigation risk even if the final drug product is approved.
- Litigation typically targets the applicant’s manufacturing disclosures, including process descriptions and impurity patterns.
Supply continuity risks
- API supply concentration creates risk for shortages.
- Batch-to-batch impurity drift can force re-testing, re-release delays, and supply interruption.
How does irbesartan/HCTZ supplier selection differ from single-ingredient sourcing?
Combination product constraints
- Tablet product requires synchronizing:
- API release specs for both irbesartan and HCTZ
- blending uniformity across actives
- coating and moisture barrier performance
- Supplier qualification must show that both actives remain stable under the applicant’s manufacturing and packaging conditions.
Key Takeaways
- Irbesartan/HCTZ supplier ecosystems break into API suppliers (irbesartan and HCTZ), irbesartan intermediate providers, and FDF tablet manufacturers.
- Regulatory readiness is driven by DMF/ASMF alignment, impurity control, and stability documentation.
- IP risk can attach to irbesartan manufacturing routes more than to standard tablet production steps.
- Combination FDF production requires tighter integration between API quality, formulation controls, and packaging selection.
FAQs
- Who manufactures irbesartan and hydrochlorothiazide tablets under contract manufacturing models?
- What quality specs matter most for irbesartan API suppliers supplying ANDA manufacturers?
- How do API impurity profiles affect bioequivalence and stability for irbesartan/HCTZ tablets?
- What packaging and moisture-barrier choices are most common for thiazide-containing combination tablets?
- Do intermediate suppliers for irbesartan create additional IP exposure compared with finished-dose suppliers?
References
- FDA. “Abbreviated New Drug Applications (ANDAs).” U.S. Food and Drug Administration. (Accessed via FDA website).
- FDA. “Drug Master Files (DMFs) and Active Ingredient Master Files (ASMFs).” U.S. Food and Drug Administration. (Accessed via FDA website).
- U.S. Patent and Trademark Office (USPTO). “Patent Searching Basics.” USPTO. (Accessed via USPTO website).
